Evidence map›Paper›PMID 31197122›Full record

ArticlePharmaceuticals (Basel, Switzerland)2019

CK2 Pro-Survival Role in Prostate Cancer Is Mediated via Maintenance and Promotion of Androgen Receptor and NFκB p65 Expression.

Janeen H Trembley, Betsy T Kren, Md J Abedin, Daniel P Shaughnessy, Yingming Li, Scott M Dehm, Khalil Ahmed

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Regulation of cancer progression by CK2: an emerging therapeutic target.Medical oncology (Northwood, London, England) · 2024
    Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Janeen H TrembleyResearch Service, Minneapolis VA Health Care System, Minneapolis, MN 55417, USA. trem0005@umn.edu.ORCID 0000-0003-3597-2611
Betsy T KrenResearch Service, Minneapolis VA Health Care System, Minneapolis, MN 55417, USA. krenx001@umn.edu.
Md J AbedinResearch Service, Minneapolis VA Health Care System, Minneapolis, MN 55417, USA. abedin@umn.edu.
Daniel P ShaughnessyResearch Service, Minneapolis VA Health Care System, Minneapolis, MN 55417, USA. shaug028@umn.edu.
Yingming LiMasonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA. lixxx354@umn.edu.
Scott M DehmDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA. dehm@umn.edu.
Khalil AhmedResearch Service, Minneapolis VA Health Care System, Minneapolis, MN 55417, USA. ahmedk@umn.edu.
University of Minnesota · USMinneapolis VA Health Care System · USUniversity of Minnesota Medical Center · US

Funding

AR Gene Rearrangements and AR Signaling in Prostate CancerR01CA174777 · NCI · UNIVERSITY OF MINNESOTA · PI Scott M. Dehm · 2013 to 2026
$4.9M
A Novel Therapeutic Approach for Primary and Metastatic Prostate CancerR01CA150182 · NCI · UNIVERSITY OF MINNESOTA · PI AHMED, KHALIL · 2011 to 2015
$1.4M
Mechanisms of CK2-regulated prostate cancer survival and deathI01BX003282 · VA · MINNEAPOLIS VA MEDICAL CENTER · PI AHMED, KHALIL · 2016 to 2019
–
BLRD VA I01 BX003282NCI NIH HHS R01 CA150182NCI NIH HHS R01 CA174777NIH HHS R01CA150182U.S. Department of Veterans Affairs BX003282
6 · The paper itself

Abstract

The prosurvival protein kinase CK2, androgen receptor (AR), and nuclear factor kappa B (NFκB) interact in the function of prostate cells, and there is evidence of crosstalk between these signals in the pathobiology of prostate cancer (PCa). As CK2 is elevated in PCa, and AR and NFκB are involved in the development and progression of prostate cancer, we investigated their interaction in benign and malignant prostate cells in the presence of altered CK2 expression. Our results show that elevation of CK2 levels caused increased levels of AR and NFκB p65 in prostate cells of different phenotypes. Analysis of TCGA PCa data indicated that AR and CK2α RNA expression are strongly correlated. Small molecule inhibition or molecular down-regulation of CK2 caused reduction in AR mRNA expression and protein levels in PCa cells and in orthotopic xenograft tumors by various pathways. Among these, regulation of AR protein stability plays a unifying role in CK2 maintenance of AR protein levels. Our results show induction of various endoplasmic reticulum stress signals after CK2 inhibition, which may play a role in the PCa cell death response. Of note, CK2 inhibition caused loss of cell viability in both parental and enzalutamide-resistant castrate-resistant PCa cells. The present work elucidates the specific link of CK2 to the pathogenesis of PCa in association with AR and NFκB expression; further, the observation that inhibition of CK2 can exert a growth inhibitory effect on therapy-resistant PCa cells emphasizes the potential utility of CK2 inhibition in patients who are on enzalutamide treatment for advanced cancer.

Indexed as

ARcell deathCK2CRPCin vivo deliverymitochondriananocapsulenanoparticleprostatesurvivalTenfibgenxenograft

Identifiers

PMID31197122
PMCPMC6631211
OpenAlexW2952784733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.